NCT04950166View on ClinicalTrials.gov

A Study to Evaluate ONM100, an Intraoperative Fluor Imaging Agent for the Detection of Peri Mets

PHASE2CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

November 30, 2021

Primary Completion Date

December 29, 2022

Study Completion Date

January 20, 2023

Conditions
Peritoneal Carcinomatosis
Interventions
DRUG

pegsitacianine

An intraoperative nanoparticle-based fluorescence imaging agent comprised of micelles covalently conjugated to indocyanine green (ICG).

Trial Locations (5)

15212

AHN Cancer Institute, West Penn Hospital, Pittsburgh

19146

Perelman School of Medicine, University of Pennsylvania, Philadelphia

27157

Wake Forest Baptist Health, Winston-Salem

43201

The Ohio State University Wexner Medical Center / James Cancer Hospital, Columbus

77030

The University of Texas MD Anderson Cancer Center, Houston

Sponsors
All Listed Sponsors
lead

OncoNano Medicine, Inc.

INDUSTRY

NCT04950166 - A Study to Evaluate ONM100, an Intraoperative Fluor Imaging Agent for the Detection of Peri Mets | Biotech Hunter | Biotech Hunter